Press Releases

November 14, 2019
BOSTON , Nov. 14, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma , Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper , President and Chief Executive Officer, will present at the Jefferies 2019 London
November 4, 2019
Senior leader with demonstrated experience building high-performing businesses and teams BOSTON , Nov. 04, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma , Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Michelle
September 30, 2019
Presentations highlight data on odevixibat’s minimal systemic exposure and Albireo’s proprietary pruritus assessment tools   BOSTON , Sept. 30, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid
September 3, 2019
BOSTON , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma , Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Simon Harford, Chief Financial Officer, will present at the 21 st Annual Rodman & Renshaw Global
August 8, 2019
— Odevixibat Phase 3 PEDFIC 1 topline results expected mid-2020 — — Initiated elobixibat Phase 2 trial in NAFLD/NASH — — Management to host conference call and webcast today at 10 a.m. EDT — BOSTON , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc.
August 6, 2019
BOSTON , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma , Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present at the Wedbush PacGrow Healthcare